Hutchison China MediTech (Chi-Med): Exercise Of Share Options

Published: Nov 30, 2016

HONG KONG, CHINA--(Marketwired - November 30, 2016) - Hutchison China Meditech Limited (NASDAQ: HCM) (AIM: HCM)

AIM/Nasdaq: HCM

Exercise of Share Options by a Person Discharging Managerial Responsibilities

London: Wednesday, November 30, 2016: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notification that Dr Weiguo Su, Executive Vice President and Chief Scientific Officer (being a Person Discharging Managerial Responsibilities), has exercised 25,535 share options (granted in 2007 and which are soon due to expire in May 2017) over ordinary shares of US$1.00 each in Chi-Med (the "Ordinary Shares") at an exercise price of GBP1.535 per share on November 25, 2016. Such Ordinary Shares will be held in the form of American Depositary Shares ("ADSs") each representing one half of one Ordinary Share.

Following the above exercise of options and subject to the completion of allotment, the holding of Dr Su is 25,535 Ordinary Shares, representing approximately 0.04% of the current issued share capital of Chi-Med, which he intends to hold as a long term investment. Additionally Dr Su holds a further 300,000 unexercised options which would represent a further 0.49% of the issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

---------------------------------------------------------------------------
1 Details of the person discharging managerial responsibilities/person     
  closely associated                                                       
---------------------------------------------------------------------------
                                                                           
a)Name                           Dr Weiguo Su                              
---------------------------------------------------------------------------
2 Reason for the notification                                              
---------------------------------------------------------------------------
                                                                           
a)Position/status                Executive Vice President and Chief        
                                 Scientific Officer of Chi-Med             
---------------------------------------------------------------------------
                                                                           
b)Initial notification/Amendment Initial notification                      
---------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant, auction    
  platform, auctioneer or auction monitor                                  
---------------------------------------------------------------------------
                                                                           
a)Name                           Hutchison China MediTech Limited          
---------------------------------------------------------------------------
                                                                           
b)LEI                            N/A                                       
---------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for (i) each type  
  of instrument; (ii) each type of transaction; (iii) each date; and (iv)  
  each place where transactions have been conducted                        
---------------------------------------------------------------------------
                                                                           
a)Description of the financial   Ordinary Shares of US$1.00 each in the    
  instrument, type of instrument form of ADSs each representing one half of
  Identification code            one Ordinary Share of US$1.00 DI ISIN:    
                                 KYG4672N1016 ADS ISIN: US44842L1035       
---------------------------------------------------------------------------
                                                                           
b)Nature of the transaction      Exercise of share options on November 25, 
                                 2016 at a price of GBP1.535 per share.    
                                 Such Ordinary Shares will be held in the  
                                 form of ADSs.                             
---------------------------------------------------------------------------
                                                                           
c)Price(s) and volume(s)                                                   
                                 ------------------------------------------
                                        Price(s)            Volume(s)      
                                 ------------------------------------------
                                        GBP1.535              25,535       
                                 ------------------------------------------
                                                                           
                                                                           
---------------------------------------------------------------------------
                                                                           
d)                               Aggregated volume: 25,535                 
  Aggregated information         Price information: GBP1.535               
                                                                           
                                                                           
  -Aggregated volume                                                       
  -Price                                                                   
                                                                           
                                                                           
---------------------------------------------------------------------------
                                                                           
e)Date of the transaction        2016-11-25                                
---------------------------------------------------------------------------
                                                                           
f)Place of the transaction       Outside a trading venue                   
---------------------------------------------------------------------------

About Chi-Med
Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

Contacts

Investor Enquiries                                                         
Christian Hogg, CEO    +852 2121 8200                                      
                                                                           
International Media                                                        
 Enquiries                                                                 
                                          anthony.carlisle@cdrconsultancy.c
Anthony Carlisle,      +44 7973 611 888   o.uk                             
Citigate Dewe Rogerson (Mobile)                                            
                                                                           
U.S. Based Media                                                           
 Enquiries                                                                 
Brad Miles,            +1 (917) 570 7340  bmiles@bmccommunications.com     
BMC Communications     (Mobile)                                            
                                                                           
Susan Duffy,           +1 (917) 499 8887  sduffy@bmccommunications.com     
BMC Communications     (Mobile)                                            
                                                                           
Investor Relations                                                         
Matt Beck,             +1 (917) 415 1750  mbeck@troutgroup.com             
The Trout Group        (Mobile)                                            
                                                                           
David Dible,           +44 7967 566 919   david.dible@citigatedr.co.uk     
Citigate Dewe Rogerson (Mobile)                                            
                                                                           
Panmure Gordon (UK)                                                        
 Limited                                                                   
Richard Gray /         +44 (20) 7886 2500                                  
Andrew Potts                                                               

Contacts:
RNS
Customer
Services
0044-207797-4400
rns@londonstockexchange.com
http://www.rns.com

Back to news